Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Enanta Pharmaceuticals reports strong Q1 earnings and advances antiviral programs

Enanta Pharmaceuticals delivered solid financial performance in Q1 2023, backed by revenue from AbbVie's MAVYRET sales and a strong cash position for future operations.
The company's focus on advancing their COVID-19 program, RSV therapeutics, and antiviral research programs demonstrates a commitment to addressing critical medical challenges.
While Enanta faces challenges in clinical development and market competition, opportunities in expanding their antiviral portfolio and presenting upcoming data offer avenues for growth.

Enanta Pharmaceuticals excels in COVID-19 treatment pipeline expansion

Enanta Pharmaceuticals showcased positive outcomes from the Phase 2 study of EDP-235 for COVID-19, emphasizing safety and symptom improvement.
The company's diversified pipeline, financial flexibility enhancement, and proactive strategic planning reflect a robust operational framework.
Challenges include demonstrating direct antiviral effects of EDP-235 and addressing regulatory and safety considerations in patient populations.
Opportunities lie in expanding therapeutic reach, capitalizing on market prospects, and addressing evolving healthcare needs in COVID-19 treatment.
Analyst interest in EDP-235's benefits, market opportunities, and patient population considerations underscores investor confidence and strategic relevance.

Enanta Pharmaceuticals reports positive Q3 results and growth opportunities

Enanta Pharmaceuticals showcased progress in RSV and COVID-19 programs with positive Phase I data.
Financially, the company reported revenue of $18.9 million and expects cash reserves to support operations into 2027.
Focus on high-risk patient populations and exploration of partnerships present growth opportunities.

Enanta Pharmaceuticals reports strong Q4 earnings, advances RSV program

Enanta Pharmaceuticals reported solid financial performance in Q4 2023, with a focus on cost reduction and strategic allocation of resources.
The company's RSV program progress and adjustments to prioritize key studies demonstrate a commitment to advancing its pipeline and making informed decisions.
While facing challenges in clinical trial recruitment and navigating the impact of COVID, Enanta remains focused on exploring new therapeutic avenues and leveraging opportunities for growth.
Ongoing discussions with the FDA, progress in key studies, and strategic decision-making underscore Enanta's efforts to drive innovation and address medical needs.

Enanta Pharmaceuticals reports Q1 revenue, progresses in RSV and immunology

Enanta Pharmaceuticals is progressing well in RSV and immunology programs, with a focus on oral treatments for respiratory syncytial virus and chronic spontaneous urticaria.
Financially, the company reported total revenue of $18 million, decreased R&D expenses, and ended the quarter with $337 million in cash and marketable securities.
Challenges include ongoing financial losses, the need for successful Phase 2 studies, and developing a best-in-disease oral KIT inhibitor.
Opportunities lie in market demand for oral treatments, entering markets with high unmet medical needs, and developing compounds with selectivity against KIT kinase.

Enanta Pharmaceuticals reports solid Q2 earnings amidst pipeline advancements

Enanta Pharmaceuticals is strategically positioned with a focus on virology and immunology, strong financial stability, and promising pipeline candidates like zelicapavir and EDP-323.
While facing challenges such as patent litigation, the company's emphasis on innovation and potential expansion into new indications presents exciting growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

After looking at interim phase 2b data, Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to stop the monotherapy trial of EDP-305 for non-alcoholic steatohepatitis (NASH). Instead, Enanta now plans to prioritize combination approaches through out-licensing arrangements.

Enanta To Discontinue Internal Development Of NASH Candidates

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs

Enanta Pharmaceuticals Provides Update on NASH FXR Agonist Programs

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Data Presentations at AASLD's The Liver Meeting® 2021

Enanta Pharmaceuticals Announces Data Presentations at AASLD's The Liver Meeting® 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors

Enanta Pharmaceuticals Elects Yujiro S. Hata to its Board of Directors

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, its Oral Hepatitis B Virus RNA Destabilizer

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer

Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q3 2021 Results - Earnings Call Transcript

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 15.60% and -1.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Misses Revenue Estimates

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19

Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter

Enanta Pharmaceuticals to Host Conference Call on August 5 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Third Quarter Ended June 30, 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.

Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral HBV RNA Destabilizer, at the International Liver Congress (EASL)

Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a HBV Core Inhibitor, in Viremic Chronic HBV Patients

Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral HBV RNA Destabilizer, at the International Liver Congress™ 2021 - EASL

Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the Liver

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference.

Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

Enanta Pharmaceuticals, Inc.'s (ENTA) CEO Jay Luly on Q2 2021 Results - Earnings Call Transcript

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced data from the first two dose cohorts of Part 2 of its Phase 1b study evaluating EDP-514 in chronic hepatitis B virus (HBV) patients already being treated with a nucleoside reverse transcriptase inhibitor (NUC). The data demonstrated that EDP-514, the Company's novel class II oral HBV core inhibitor, was safe and well-tolerated, displayed pharmacokinetics (PK) supportive of once-daily dosing, and resulted in a mean reduction in HBV RNA of 1 log.

Enanta's EDP-514 Four-Week Treatment Shows Around 10 Time Reduction In Hepatitis B Virus RNA

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic HBV Patients on NUC Treatment

Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic Hepatitis B Virus Patients on Treatment with a Nucleoside Reverse Transcriptase Inhibitor

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2021

Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2021

Enanta's huge cash holdings are very desirable in an uncertain economic world and overvalued U.S. stock market setup. The drug trial pipeline could have several positive news developments in the coming months.

The Bottom Fishing Club: Enanta Pharmaceuticals

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference

Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q1 2021 Results - Earnings Call Transcript

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 163.08% year over year to ($0.41), which beat the estimate of ($0.74).

News for Enanta Pharmaceuticals Stock (ENTA)